Stock Analiz

SkinHealth Systems Inc. SKIN

Medical/Dental Instruments · IPO 2020 · data as of November 13, 2026

$16.31Market cap $107M
Open the interactive analysis →

SkinHealth Systems Inc. (SKIN) is a healthcare company listed in the US with a market value of about $107M. In the twelve months to September 30, 2026 it had revenue of $289M and net income of -$18M, a net margin of -6.3%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is value (3/5); the weakest is future growth (1/5).

Key numbers: a P/E of 9.3, a price to free cash flow of 4.7, 5-year revenue growth of 20% a year, a 5-year average ROIC of -8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 11% below the current price.

About SkinHealth Systems

SkinHealth Systems is listed in the US and classified in medical/dental instruments, IPO year 2020. Revenue went from $167M in 2019 to $301M in 2025, growth of about 10.3% a year. It was profitable in 1 of the last 7 years in our data. Its share count fell by 9% over three years (buybacks). It spends 2% of revenue on research and development.

Score: 1.4 / 5

Value3/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Profit margin improving
  • 5-year revenue growth above 8% a year
  • Positive free cash flow
  • Share count down over 3 years (buybacks)

Checks not passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)9.3
Forward P/E—
P/FCF4.7
P/S0.4
P/B1.9
EV/EBITDA9.3
PEG—
Dividend yield0.00%
FCF yield21.3%
Shareholder yield0.0%
Intrinsic value vs. price−11%

Growth and quality

Revenue growth (1 yr)-10.0%
Revenue growth (5 yrs, per year)20.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-34.1%
ROIC (5-yr avg.)-7.7%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$289M$301M$334M$398M$366M$260M$119M$167M
Net income-$18M-$10M-$29M-$100M$44M-$379M-$29M-$2M
Free cash flow$23M$37M$15M$18M-$117M-$40M-$16M-$7M
EPS (diluted)$1.75$-0.16$-0.36$-0.76$-0.23$-3.71$-0.85$-0.05
Net margin-6.3%-3.2%-8.7%-25.2%12.1%-145.6%-24.5%-1.0%
ROIC—-5.2%-10.8%-15.8%-2.7%-3.8%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is SkinHealth Systems’s P/E ratio?

About 9.3, based on the last twelve months of diluted earnings per share.

Is SkinHealth Systems stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 11% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does SkinHealth Systems pay a dividend?

Not currently.

Is SkinHealth Systems a good stock to buy?

We do not give buy or sell advice. SkinHealth Systems scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.